All In Biotech

Drug Trial Radar · NCT04003857

Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial

Last checked: Nov 20, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 5, 2019

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Medipost Co Ltd.Industry
Sponsor type
Industry
First posted
Jul 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 60 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a follow-up study to investigate the long-term safety and efficacy of PNEUMOSTEM® versus placebo, for the treatment of BPD in premature infants. Subjects who participated in and completed the initial stage of the Phase II trial (NCT03392467) will be followed-up until 60 months of corrected age

Conditions

  • Bronchopulmonary Dysplasia
  • BPD

Interventions

  • PNEUMOSTEM®Biological

    A single intratracheal administration of PNEUMOSTEM® (1.0 x 10\^7 cells/kg)

  • normal salineBiological

    A single intratracheal administration of normal saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Respiratory outcome: Number of hospitalizationsTime frame: 6 months corrected age
  2. Respiratory outcome: Number of hospitalizationsTime frame: 12 months corrected age
  3. Respiratory outcome: Number of hospitalizationsTime frame: 18 months corrected age
  4. Respiratory outcome: Number of hospitalizationsTime frame: 24 months corrected age
  5. Respiratory outcome: Number of hospitalizationsTime frame: 36 months after birth
  6. Respiratory outcome: Number of hospitalizationsTime frame: 39 months after birth
  7. Respiratory outcome: Number of hospitalizationsTime frame: 42 months after birth
  8. Respiratory outcome: Number of hospitalizationsTime frame: 45 months after birth
  9. Respiratory outcome: Number of hospitalizationsTime frame: 48 months after birth
  10. Respiratory outcome: Number of hospitalizationsTime frame: 51 months after birth
  11. Respiratory outcome: Number of hospitalizationsTime frame: 54 months after birth
  12. Respiratory outcome: Number of hospitalizationsTime frame: 57 months after birth
  13. Respiratory outcome: Number of hospitalizationsTime frame: 60 months after birth

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.